Antibody-based identification of cell surface antigens: targets for cancer therapy.
The identification of novel cell surface antigens present on tumor cells is crucial for developing new cancer therapies. Intact, viable cancer cells, which display cancer-restricted antigens in their native conformation and cellular context, provide a rich source of novel antigens. Antibody-based technologies are being used to probe the surface of intact cancer cells for cancer-specific antigen targets. In addition to identifying new proteins, these approaches are generating monoclonal antibodies (MAbs) to cancer-specific epitopes and nonprotein targets not amenable to genomics-based approaches. The multiple cell-based approaches developing epitope-specific MAbs to cancer antigens is likely to usher in a new era of therapeutic MAb target discovery.
Loo
Deryk T
DT
Raven Biotechnologies, Inc., One Corporate Drive, South San Francisco, CA 94080, USA.
Mather
Jennie P
JP
D000818:Animals; D000906:Antibodies / Q000737:chemistry; D000954:Antigens, Surface / Q000737:chemistry / Q000187:drug effects* / Q000276:immunology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D023281:Genomics; D006801:Humans; D040901:Proteomics
D000906:Antibodies; D000954:Antigens, Surface; D000970:Antineoplastic Agents